Joe Wiley, CEO of Amryt Pharma talks about their record Q3 Results & raised FY revenue guidance.

Joe Wiley, CEO of Amryt Pharma #AMYT talks about their record Q3 Results where they've raised FY 2020 revenue guidance.

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.